Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial | Synapse
March 3, 2026Open Access
Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial
Puntos clave
Responses were observed in acute lymphoblastic leukemia with the combination of selumetinib and dexamethasone, indicating potential efficacy.
The Phase I/II trial included dose-finding aspects and parallel cohort assessments, enhancing the robustness of findings.
Selumetinib, a MEK inhibitor, may be a critical intervention targeting the RAS-pathway mutations in leukemia patients.
Combination treatments like this one may provide new hope for patients facing relapsed or refractory leukemia.